Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2017. The document serves as a transaction notification regarding a specific executive compensation event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. The only financial data disclosed relates to a specific transaction involving a Person Discharging Managerial Responsibilities (PDMR):
- Transaction Type: Cash payment following the vesting of a Deferred Investment Award.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 14,940 notional ordinary shares.
- Price: £15.850 per share.
- Total Value: £236,799 (gross, before applicable tax withholding).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents the vesting of an award made on September 24, 2014, which occurred on February 12, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a single transaction involving Mr. N Hirons, SVP, Global Ethics & Compliance.
Investor Verification Points
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Plan referenced in the filing.
- Confirm the tax withholding implications for the £236,799 gross payment to Mr. Hirons.
- Note that this filing does not reflect the company's overall financial performance for the period; refer to Form 20-F for comprehensive financial statements.